News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘ProstateCancer’ clear

  • Men with metastatic, hormone-sensitive prostate cancer gained more than a year of survival when they received both hormone-blocking medications and chemotherapy right after diagnosis, rather than delaying the chemo until the cancer worsened, according to a study led by Dana-Farber’s Christopher Sweeney published in the New England Journal of Medicine.

Tags: chemotherapy, ProstateCancer

  • First study of the genomic composition of prostate cancer shows many patients have gene mutations that can be targeted with existing or potential drugs.

Tags: Genomics, ProstateCancer, TargetedTherapy

  • Dana-Farber's Levi Garraway, MD, PhD, has been selected as one of 26 Howard Hughes Medical Institute investigators.

Tags: Genomics, Honors, ProstateCancer

  • New research suggests that cholesterol-lowering statin drugs could be a valuable addition to current therapies for prostate cancer.

Tags: ProstateCancer

  • Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health in Boston and the Irish Cancer Society have formed the Boston-Ireland Prostate Cancer Collaboration. This new entity will conduct and facilitate exchanges of researchers and knowledge between Boston and Ireland.

Tags: BasicResearch, ProstateCancer

  • Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

Tags: EGFR, Genomics, LungCancer, OvarianCancer, ProstateCancer, Lymphoma, Immunotherapy

  • Practice-changing clinical research conducted at the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology was featured at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.

Tags: BreastCancer, ProstateCancer

  • Dana-Farber researchers and colleagues report that men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting for the disease to become resistant to hormone-blockers.

Tags: ProstateCancer

  • Dana-Farber researchers find many men with low-risk, localized prostate cancers can safely choose observation instead of undergoing immediate treatment and have a better quality of life while reducing health care costs.

Tags: ProstateCancer, PopulationScience

  • Researchers at Dana-Farber/Brigham and Women's Cancer Center report a small percentage of men in a prostate cancer study complained that their penis seemed shorter following treatment, causing them to regret the type of treatment they chose.

Tags: ProstateCancer, PopulationScience

Showing 1-10 of 27 items